Discuss the key indications, risk factors for survival and adverse events for destination therapy for the management of end-stage heart failure (HF). |
|
|
|
|
|
|
List key elements of institutional infrastructure to support HF destination therapy and regulatory requirements to perform HF destination therapy. |
|
|
|
|
|
|
Implement strategies to support management of end-stage heart failure (HF) for the non-transplant candidate, and improve patient outcomes. |
|
|
|
|
|
|